Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Overview Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development Daiichi Sankyo Co Ltd EntreChem SL IMMD Inc Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Drug Profiles 13-197 - Drug Profile Product Description Mechanism Of Action R&D Progress EC-70124 - Drug Profile Product Description Mechanism Of Action R&D Progress IMD-0560 - Drug Profile Product Description Mechanism Of Action R&D Progress IMD-2560 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit IKBKB for Inflammation and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit IKKb for Glioblastoma Multiforme - Drug Profile Product Description Mechanism Of Action R&D Progress TLX-1423 - Drug Profile Product Description Mechanism Of Action R&D Progress Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Dormant Products Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Discontinued Products Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones Featured News & Press Releases Jan 17, 2018: EntreChem reports potent activity of EC-70124 in Acute Myeloid Leukemia Mar 10, 2016: EntreChem's orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kinase Inhibitor EC-70124 At 2013 AACR Annual Meeting Mar 26, 2012: EntreChem's Kinase Inhibitor Shows Potential For Treatment Of Head And Neck Cancer May 09, 2011: EntreChem's Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma Feb 15, 2009: IMMD Completes Phase I Clinical Trial Of IMD-2560 In UK Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Daiichi Sankyo Co Ltd, H1 2018 Pipeline by EntreChem SL, H1 2018 Pipeline by IMMD Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Daiichi Sankyo Co Ltd EntreChem SL IMMD Inc